Global Glioblastoma Multiforme Treatment Industry Outlook 2022: Overview, Opportunities, Key Companies and Forecast to 2028
Executive Summary
According to GRD Survey data, the global Glioblastoma Multiforme Treatment market is estimated at million US$ in 2021 and is expected to million US$ by the end of 2028, growing at a CAGR of % in the forecast period from 2022 to 2028.
This report studies the Glioblastoma Multiforme Treatment market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (Million USD) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with revenue, market share and growth Rate of Glioblastoma Multiforme Treatment in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)
Market Snapshot, By Product Type
Bevacizumab (Avastin)
Carmustine (BiCNU)
Temozolomide (Temodar and Temodal and Temcad)
Market Snapshot, By Application
Hospital
Clinic
Others
Main Market Players Analyzed in this report, including:
F. Hoffmann-La Roche Ltd.
Exelixis Inc
Cortice Biosciences
Celldex Therapeutics Inc
Cavion LLC
Bristol-Myers Squibb Company
Arog Pharmaceuticals, Inc
Agenus Inc
Activartis GmbH
AbbVie, Inc
The study objectives of this report are:
To study and analyze the global Glioblastoma Multiforme Treatment market size (Million USD) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Glioblastoma Multiforme Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Glioblastoma Multiforme Treatment manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Glioblastoma Multiforme Treatment market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Glioblastoma Multiforme Treatment submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Glioblastoma Multiforme Treatment are as follows:
History Year: 2016-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2027
This report includes the estimation of market size from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries
Table of Content
Table of Contents
1 Market Definition & Scope
1.1 Definition & Scope
1.2 Glioblastoma Multiforme Treatment Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Glioblastoma Multiforme Treatment Market Performance and Outlook
2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Glioblastoma Multiforme Treatment
3 3 Industrial Lift Cycle and Main Buyers Analysis
3.1 Industry Life Cycle Analysis
3.2 Key Buying Industries/Consumers
3.2.1 Major Buyers in Hospital
3.2.2 Major Buyers in Clinic
4 Market Segment: by Type
4.1 Glioblastoma Multiforme Treatment Type Introduction
4.1.1 Bevacizumab (Avastin)
4.1.2 Carmustine (BiCNU)
4.1.3 Temozolomide (Temodar and Temodal and Temcad)
4.2 Global Glioblastoma Multiforme Treatment Revenue by Type 2016-2021
5 Market Segment: by Application
5.1 Glioblastoma Multiforme Treatment Type Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Others
5.2 Global Glioblastoma Multiforme Treatment Revenue by Application 2016-2021
6 Marke Segment: by Region
6.1 Global Glioblastoma Multiforme Treatment Market by Region
6.2 North America Glioblastoma Multiforme Treatment Market 2016-2021
6.3 Europe Glioblastoma Multiforme Treatment Market 2016-2021
6.4 Asia Pacific Glioblastoma Multiforme Treatment Market 2016-2021
6.5 South America Glioblastoma Multiforme Treatment Market 2016-2021
6.6 Middle East and Africa Glioblastoma Multiforme Treatment Market 2016-2021
7 North America
7.1 North America Glioblastoma Multiforme Treatment Market by Country 2016-2021
7.2 United States
7.3 Canada
7.4 Mexico
8 Europe
8.1 Europe Glioblastoma Multiforme Treatment Market by Country 2016-2021
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain
9 Asia Pacific
9.1 Asia Pacific Glioblastoma Multiforme Treatment Market by Country 2016-2021
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia
10 South America
10.1 South America Glioblastoma Multiforme Treatment Market by Country 2016-2021
10.2 Brazil
10.3 Argentina
10.4 Colombia
11 Middle East and Africa
11.1 Middle East and Africa Glioblastoma Multiforme Treatment Market by Country 2016-2021
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa
12 Key Participants Company Information
12.1 F. Hoffmann-La Roche Ltd.
12.1.1 F. Hoffmann-La Roche Ltd. Company Information
12.1.2 F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Product Portfolio, Specification and Application
12.1.3 F. Hoffmann-La Roche Ltd. Glioblastoma Multiforme Treatment Revenue and Gross Margin (2019-2021)
12.1.4 F. Hoffmann-La Roche Ltd. Key Development
12.2 Exelixis Inc
12.2.1 Exelixis Inc Company Information
12.2.2 Exelixis Inc Glioblastoma Multiforme Treatment Product Portfolio, Specification and Application
12.2.3 Exelixis Inc Glioblastoma Multiforme Treatment Revenue and Gross Margin (2019-2021)
12.2.4 Exelixis Inc Key Development
12.3 Cortice Biosciences
12.3.1 Cortice Biosciences Company Information
12.3.2 Cortice Biosciences Glioblastoma Multiforme Treatment Product Portfolio, Specification and Application
12.3.3 Cortice Biosciences Glioblastoma Multiforme Treatment Revenue and Gross Margin (2019-2021)
12.3.4 Cortice Biosciences Key Development
12.4 Celldex Therapeutics Inc
12.4.1 Celldex Therapeutics Inc Company Information
12.4.2 Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Product Portfolio, Specification and Application
12.4.3 Celldex Therapeutics Inc Glioblastoma Multiforme Treatment Revenue and Gross Margin (2019-2021)
12.4.4 Celldex Therapeutics Inc Key Development
12.5 Cavion LLC
12.5.1 Cavion LLC Company Information
12.5.2 Cavion LLC Glioblastoma Multiforme Treatment Product Portfolio, Specification and Application
12.5.3 Cavion LLC Glioblastoma Multiforme Treatment Revenue and Gross Margin (2019-2021)
12.5.4 Cavion LLC Key Development
12.6 Bristol-Myers Squibb Company
12.6.1 Bristol-Myers Squibb Company Company Information
12.6.2 Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Product Portfolio, Specification and Application
12.6.3 Bristol-Myers Squibb Company Glioblastoma Multiforme Treatment Revenue and Gross Margin (2019-2021)
12.6.4 Bristol-Myers Squibb Company Key Development
12.7 Arog Pharmaceuticals, Inc
12.7.1 Arog Pharmaceuticals, Inc Company Information
12.7.2 Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Product Portfolio, Specification and Application
12.7.3 Arog Pharmaceuticals, Inc Glioblastoma Multiforme Treatment Revenue and Gross Margin (2019-2021)
12.7.4 Bristol-Myers Squibb Company Key Development
12.9 Activartis GmbH
12.9.1 Activartis GmbH Company Information
12.9.2 Activartis GmbH Glioblastoma Multiforme Treatment Product Portfolio, Specification and Application
12.9.3 Activartis GmbH Glioblastoma Multiforme Treatment Revenue and Gross Margin (2019-2021)
12.9.4 Activartis GmbH Key Development
12.8 Agenus Inc
12.8.1 Agenus Inc Company Information
12.8.2 Agenus Inc Glioblastoma Multiforme Treatment Product Portfolio, Specification and Application
12.8.3 Agenus Inc Glioblastoma Multiforme Treatment Revenue and Gross Margin (2019-2021)
12.8.4 Agenus Inc Key Development
13 Global Glioblastoma Multiforme Treatment Market Forecast by Region by Type and by Application
13.1 Global Glioblastoma Multiforme Treatment Revenue Forecast 2022-2027
13.2 Global Glioblastoma Multiforme Treatment Forecast by Regions
13.3 Global Glioblastoma Multiforme Treatment Forecast by Type
13.4 Global Glioblastoma Multiforme Treatment Forecast by Application
14 Analyst Views and Conclusions
15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices